'Opioids Cause Pain. Full Stop.': What We Heard This Week
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

MedPage Today published a Nov. 15, 2026, roundup of comments from clinicians and health leaders on several medical and public-health developments. Topics included opioid treatment for sickle cell disease pain, a boycott of the American Diabetes Association, a lawsuit alleging safety concerns about resmetirom, vaccine policy and prostate cancer screening.

MedPage Today published a weekly roundup of comments on Nov. 15, 2026, featuring remarks about opioid treatment for sickle cell disease pain, an ongoing boycott of the American Diabetes Association and other health-policy and clinical issues. The collection records what named clinicians and health leaders said; it is not a single study or formal clinical guideline.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The roundup’s headline quote came from Jeffrey Glassberg, MD, of the Icahn School of Medicine at Mount Sinai in New York City, speaking about opioid use to treat pain in sickle cell disease. He said: “Opioids cause pain. Full stop.” The brief report does not provide details of the discussion, evidence cited or specific treatment recommendations, so the remark should be read as a quoted viewpoint rather than a full account of clinical guidance.

Other entries addressed organizational disputes and drug safety. Christian Kohler, who had resigned as vice president of publications at the American Diabetes Association, said the organization’s boycotters were engaged in “not a frivolous exercise.” At the annual Liver Meeting, David Goldberg, MD, of the University of Miami’s Miller School of Medicine, referred to a whistleblower lawsuit alleging safety concerns about resmetirom, sold as Rezdiffra, a drug for metabolic dysfunction-associated steatohepatitis. The roundup reports the existence of the allegation, not a finding that the concerns have been established.

The remaining remarks covered sleep disorders, public understanding of autism, vaccines, cancer screening and medication use. Sleep specialist Anne Marie Morse, DO, said patients’ descriptions of brain fog should be treated as symptoms in their own right. Public-health leaders criticized beliefs about autism and a delayed federal vaccine report, while a physician pointed to clearer prostate-screening guidance and an Australian researcher said pregabalin use remained too high despite signs that a rise in gabapentinoid use was reversing.

At a glance
recapWhen: Published Nov. 15, 2026
The developmentMedPage Today published its weekly collection of notable comments from reporters’ interviews and medical meetings on Nov. 15, 2026.

Clinical Views and Policy Disputes

The roundup offers a snapshot of issues being debated across medicine, but its short quotations do not resolve them. The opioid comment touches a high-stakes question for people with sickle cell disease: how clinicians should respond to severe pain while weighing treatment risks. The source gives no clinical evidence or guidance alongside Glassberg’s statement, so readers should not treat the quote alone as a treatment rule.

The other comments also point to matters with consequences beyond individual clinical decisions. A boycott can affect an organization’s activities and reputation; allegations involving a drug can prompt scrutiny, but allegations are not proof. Disagreement over vaccines and screening guidelines can shape public confidence and care decisions. The roundup is useful as a record of what speakers said, while the underlying evidence and developments require separate reporting.

Products Worth Considering

Garmin Forerunner 265 GPS Running Smartwatch, 46 mm, Black/Powder Gray

Garmin Forerunner 265 GPS Running Smartwatch, 46 mm, Black/Powder Gray

Garmin Forerunner 970 GPS Running and Triathlon Smartwatch, 47mm, Carbon Gray DLC Titanium with Black/Whitestone Band

Garmin Forerunner 970 GPS Running and Triathlon Smartwatch, 47mm, Carbon Gray DLC Titanium with Black/Whitestone Band

As an affiliate, we earn on qualifying purchases.

Eight Remarks Across Health News

MedPage Today presented the material as a collection of quotable comments heard by its reporters, rather than as a unified investigation. Its entries span different settings: a specialist’s discussion of sickle cell pain, the American Diabetes Association boycott, comments at the annual Liver Meeting, and remarks on public-health beliefs, federal vaccine policy, prostate screening and prescribing in Australia.

The source identifies the speakers and, in several cases, their institutions or roles. It does not supply full interview transcripts, supporting data, the complete circumstances behind each quotation or links to the underlying documents. Those limits matter: comments about a lawsuit, a survey, a guideline update or prescribing trends are not substitutes for the primary records or research.

““This is not a frivolous exercise for the boycotters.””

— Christian Kohler, former vice president of publications at the American Diabetes Association

Evidence Behind the Brief Quotes

The roundup does not establish whether the statements represent consensus among specialists or provide enough detail to evaluate the evidence behind them. It gives no treatment data alongside Glassberg’s opioid comment, and it does not specify the scope or status of the allegations in the resmetirom whistleblower lawsuit. The lawsuit’s claims remain allegations in this source.

Several references also lack detail needed to assess their implications. The report does not describe the survey behind the finding that roughly one in four U.S. adults believe myths about autism risk, reproduce the delayed vaccine task force report or identify the precise prostate-screening changes. It does not give the data, timeframe or comparison baseline for the Australian pregabalin trend. Further reporting or primary sources would be needed to answer those questions.

Follow the Underlying Decisions

The roundup itself announces no scheduled follow-up. Readers seeking developments can look to the underlying proceedings and records: updates on the American Diabetes Association boycott, any further information about the resmetirom lawsuit, publication of the federal vaccine task force report, and the full prostate-screening guidance. Clinical questions about pain treatment should be assessed through detailed evidence and guidance from qualified clinicians, rather than one quotation.

For the trends on autism beliefs and pregabalin use, the next useful information would include the original survey and prescribing data, including dates and comparison baselines. Until those details are available in the cited material, the comments are best understood as a weekly snapshot of views and developing debates, not final findings.

Key Questions

What did Jeffrey Glassberg say about opioids and sickle cell disease pain?

Glassberg said, “Opioids cause pain. Full stop,” while commenting on opioid use to treat sickle cell disease pain. The roundup does not include a full explanation, evidence review or treatment recommendation.

Does the roundup establish safety problems with resmetirom?

No. It says David Goldberg referred to a whistleblower lawsuit alleging safety concerns about resmetirom, also sold as Rezdiffra. The brief report does not establish that the allegations are true.

What other topics did the weekly collection cover?

It included the American Diabetes Association boycott, sleep-related brain fog, beliefs about autism, a delayed federal vaccine report, prostate cancer screening and pregabalin use in Australia.

When was the collection published?

MedPage Today’s roundup was published on Nov. 15, 2026. The source presents it as a collection of comments heard by the publication’s reporters.

Source: medpagetoday.com

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

Hawaii Doctors May Soon Start Prescribing Fresh Food

Hawaii plans to start a Medicaid Food Is Medicine program in January, offering eligible patients nutrition education and fresh food boxes.

How to Eat for Back-to-Back Training Days

Maintaining optimal nutrition for back-to-back training days is crucial, but discovering the best strategies can significantly boost your performance and recovery.

Three Of The Best Hip Mobility Moves To Do If You Sit Down All Day

Fit&Well recommends three equipment-free hip mobility exercises for people who spend long periods sitting, with guidance on frequency and safety.

Pfizer Surges In Global Coverage

Media coverage of Pfizer has increased significantly, with 32 mentions in recent reports—an 8.8-fold rise. The cause remains unconfirmed but signals heightened public and media interest.